retatrutide patent eli lilly Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide: Eli Lilly's Bold Gamble

PubMed PMID: 38945189

are maintained at such artificially high levels compared to every other large-market country in the world, restricting demand for brand-name meds but increasing demand for compounded meds. We call on policymakers and regulators to take into account this increase in demand and maintain compounding exemptions until the price of the brand-name medications in New York and Los Angeles match their price in London and Sydney

See our Compliance Policy

But for people who hate needles, these medications hold a glaring, obvious drawback: They require taking a weekly shot

For patients and clinicians, this matters because it changes how we think about outcomes

Retatrutide: Phase 2 (48 Weeks) and Phase 3 TRIUMPH-4 (68 Weeks) Retatrutide has two major datasets